Neurogene Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Neurogene Inc. (NGNE) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 86.77% for the 9-month period ending 2023-09-30, per its 10-Q filed 2023-11-14.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2023-11-14
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-06-30 was 87.37%, a 5.67% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2023-03-31 was 85.95%, a 3.33% increase year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-09-30 was 84.18%, a 5.60% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2022-06-30 was 82.68%, a 7.23% decline year-over-year.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 84.00%, a 5.62% decline from fiscal 2021.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2021 was 89.00%, a 4.30% decline from fiscal 2020.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2020 was 93.00%, a 3.33% increase from fiscal 2019.
- Neurogene Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2019 was 90.00%, a 12.50% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 123 month |
|---|---|---|---|---|---|
| 2023-09-30 | 86.77% 10-Q · filed 2023-11-14 | ||||
| 2023-06-30 | 87.37% 10-Q · filed 2023-08-10 | 86.77% 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | 85.95% 10-Q · filed 2023-05-08 | ||||
| 2022-12-31 | 84.00% 10-K · filed 2023-03-20 | ||||
| 2022-09-30 | 84.18% 10-Q · filed 2023-11-14 | 83.80% 10-Q · filed 2023-11-14 | |||
| 2022-06-30 | 82.68% 10-Q · filed 2023-08-10 | 83.01% 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | 83.18% 10-Q · filed 2023-05-08 | ||||
| 2021-12-31 | 89.00% 10-K · filed 2023-03-20 | ||||
| 2021-09-30 | 89.17% 10-Q · filed 2022-11-14 | 89.18% 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | 89.12% 10-Q · filed 2022-08-09 | 89.19% 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | 89.68% 10-Q · filed 2022-05-09 | ||||
| 2020-12-31 | 93.00% 10-K · filed 2022-03-01 | ||||
| 2020-09-30 | 94.84% 10-Q · filed 2021-11-04 | 93.86% 10-Q · filed 2021-11-04 | |||
| 2020-06-30 | 93.61% 10-Q · filed 2021-08-05 | 92.09% 10-Q · filed 2021-08-05 | |||
| 2020-03-31 | 90.00% 10-Q · filed 2021-05-12 | ||||
| 2019-12-31 | 90.00% 10-K · filed 2021-03-25 | ||||
| 2019-09-30 | 90.00% 10-Q · filed 2020-11-09 | 90.00% 10-Q · filed 2020-11-09 | |||
| 2018-12-31 | 80.00% 10-K · filed 2020-03-12 | ||||
| 2018-09-30 | 83.00% 10-Q · filed 2019-11-13 | 80.00% 10-Q · filed 2019-11-13 | |||
| 2018-06-30 | 86.00% 10-Q · filed 2019-08-01 | 77.00% 10-Q · filed 2019-08-01 | |||
| 2018-03-31 | 75.00% 10-Q · filed 2019-05-07 | ||||
| 2017-12-31 | 84.00% 10-K · filed 2020-03-12 | ||||
| 2017-09-30 | 91.00% 10-Q · filed 2018-11-07 | 91.00% 10-Q · filed 2018-11-07 | |||
| 2017-06-30 | 90.00% 10-Q · filed 2018-08-08 | 91.00% 10-Q · filed 2018-08-08 | |||
| 2017-03-31 | 91.00% 10-Q · filed 2018-05-08 | ||||
| 2016-12-31 | 82.00% 10-K · filed 2019-03-07 | ||||
| 2016-09-30 | 87.00% 10-Q · filed 2017-11-08 | 81.00% 10-Q · filed 2017-11-08 | |||
| 2016-06-30 | 79.00% 10-Q · filed 2017-08-08 | 80.00% 10-Q · filed 2017-08-08 | |||
| 2016-03-31 | 80.00% 10-Q · filed 2017-05-09 | ||||
| 2015-12-31 | 97.00% 10-K · filed 2018-03-12 | ||||
| 2015-09-30 | 98.00% 10-Q · filed 2016-11-09 | ||||
| 2015-06-30 | 95.00% 10-Q · filed 2016-08-04 | 98.00% 10-Q · filed 2016-08-04 | |||
| 2015-03-31 | 98.00% 10-Q · filed 2016-05-10 | ||||
| 2014-12-31 | 108.00% 10-K · filed 2017-03-09 | ||||
| 2014-09-30 | 108.00% 10-Q · filed 2015-11-10 | 108.00% 10-Q · filed 2015-11-10 | |||
| 2014-06-30 | 108.00% 10-Q · filed 2015-08-06 | 108.00% 10-Q · filed 2015-08-06 | |||
| 2014-03-31 | 108.00% 10-Q · filed 2015-05-12 | 88.00% 10-Q · filed 2014-05-13 | |||
| 2013-12-31 | 94.00% 10-K · filed 2016-03-14 | ||||
| 2013-09-30 | 93.00% 10-Q · filed 2014-11-04 | ||||
| 2013-06-30 | 93.00% 10-Q · filed 2014-08-11 | 93.00% 10-Q · filed 2014-08-11 | |||
| 2012-12-31 | 90.00% 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |